Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Emervel for the Correction of Lower Face Wrinkles & Folds: Complete Statistical AnalysisIndependent statistical analysis of Emervel for the Correction of Lower Face Wrinkles & Folds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02718040).
- Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds: Complete Statistical AnalysisIndependent statistical analysis of Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EmiandMeIndependent statistical analysis of An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families: primary endpoint results, effect estimate with confidence interval, sample-size…
- EMILIIndependent statistical analysis of Evaluating Muscle Weakness Improvement With Lorcaserin in ICU: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02523690).
- EMILIAIndependent statistical analysis of A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- EMIXIndependent statistical analysis of Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01352585).
- Emla-Cream as Pain Relief During Pneumococcal Vaccination: Complete Statistical AnalysisIndependent statistical analysis of Emla-Cream as Pain Relief During Pneumococcal Vaccination: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01802086).
- EMMAIndependent statistical analysis of Extracellular Matrix Marker of Arrhythmia Risk (EMMA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00376532).
- EMMYIndependent statistical analysis of Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- EMMYIndependent statistical analysis of Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Emotion Regulation Interventions for Alcohol-Related Sexual Aggression: Complete Statistical AnalysisIndependent statistical analysis of Emotion Regulation Interventions for Alcohol-Related Sexual Aggression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03159468).
- EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin): Complete Statistical AnalysisIndependent statistical analysis of EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03594110).
- EMPACT-MIIndependent statistical analysis of EMPACT-MI, the randomized, placebo-controlled phase 3 trial of empagliflozin 10 mg after myocardial infarction: covariate-adjusted Cox hazard ratio for heart failure hospitalisation or death, negative binomial rate ratios…
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction): Complete Statistical AnalysisIndependent statistical analysis of EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction): primary endpoint results,…
- EMPACTAIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus: Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study: Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02632747).
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): Complete Statistical AnalysisIndependent statistical analysis of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): Complete Statistical AnalysisIndependent statistical analysis of EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- EMPATHYIndependent statistical analysis of A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EMPHASISIndependent statistical analysis of Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EMPIREIndependent statistical analysis of A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- EMPiREIndependent statistical analysis of GORE Embolic Protection With Reverse Flow: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00594100).
- EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: Complete Statistical AnalysisIndependent statistical analysis of EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients: primary endpoint results, effect estimate with confidence…
- EMPOWERIndependent statistical analysis of Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- EMPOWER CADIndependent statistical analysis of Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- EMPOWER-EDIndependent statistical analysis of Promoting Benzodiazepine Cessation Through an Electronically-delivered Patient Self-management Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04572750).
- EMPOWER-MomIndependent statistical analysis of Postpartum Weight Loss for Women at Elevated Cardiovascular Risk: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04914819).
- EMPOWER-T2DIndependent statistical analysis of EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04531176).
- Empowering LGBTQ+ Tobacco Cessation Pilot: Complete Statistical AnalysisIndependent statistical analysis of Empowering LGBTQ+ Tobacco Cessation Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05365633).
- EMPWRIndependent statistical analysis of Eating Mindfully to Prevent Weight Regain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04847843).
- EMRI SureScan™ Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of EMRI SureScan™ Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00433654).
- EMSUPIndependent statistical analysis of Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- EMTIndependent statistical analysis of Enhanced Community-Based Asthma Monitoring Through Novel Technology: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05824936).
- En-GARDEIndependent statistical analysis of Post-Market Randomized Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01057394).
- ENAC Blockade and Arterial Stiffness: Complete Statistical AnalysisIndependent statistical analysis of ENAC Blockade and Arterial Stiffness: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03837626).
- EnACTIndependent statistical analysis of Developing and Testing the Enhancing Active Caregiver Training (EnACT) Intervention for Dementia Family Caregivers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- ENACT-aMCIIndependent statistical analysis of ENgaging in Advance Care Planning Talks Group Visit Intervention for Cognitive Impairment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: Complete Statistical AnalysisIndependent statistical analysis of Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05282459).
- ENB-GS-TBLB for the Diagnosis of PPLs: Complete Statistical AnalysisIndependent statistical analysis of ENB-GS-TBLB for the Diagnosis of PPLs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02207478).
- Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00778648).
- ENCOREIndependent statistical analysis of A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE): primary endpoint results, effect estimate with confidence…
- ENCOREIndependent statistical analysis of Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ENCOREIndependent statistical analysis of Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- ENCORE-VTIndependent statistical analysis of Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- END-ITIndependent statistical analysis of Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.